Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
32.40
+0.29 (+0.90%)
Streaming Delayed Price
Updated: 11:14 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story
↗
December 27, 2025
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story
Via
The Motley Fool
Topics
Regulatory Compliance
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
↗
December 24, 2025
Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.
Via
The Motley Fool
Topics
Artificial Intelligence
My Top 10 Portfolio Holdings for 2026
↗
December 19, 2025
This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.
Via
The Motley Fool
Topics
Stocks
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
↗
December 17, 2025
Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.
Via
The Motley Fool
Topics
Intellectual Property
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
↗
December 14, 2025
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
Via
The Motley Fool
Topics
Intellectual Property
Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop
↗
December 09, 2025
Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing
↗
December 09, 2025
Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.
Via
The Motley Fool
Topics
Regulatory Compliance
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
December 03, 2025
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...
Via
MarketMinute
Topics
Artificial Intelligence
Death
Intellectual Property
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
↗
November 30, 2025
Stanley Druckenmiller is considered one of the greatest investors of all time.
Via
The Motley Fool
Topics
Artificial Intelligence
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared
↗
November 27, 2025
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.
Via
Stocktwits
Topics
ETFs
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets
↗
November 26, 2025
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.
Via
Stocktwits
Topics
Economy
Government
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied
↗
November 26, 2025
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.
Via
Investor's Business Daily
Topics
Economy
Government
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report
↗
November 19, 2025
Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.
Via
Benzinga
Topics
Law Enforcement
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves
↗
November 14, 2025
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 11, 2025
Via
Benzinga
Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023
↗
November 11, 2025
Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.
Via
The Motley Fool
Topics
Artificial Intelligence
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
↗
November 10, 2025
Via
Benzinga
Price Over Earnings Overview: Teva Pharmaceutical Indus
↗
November 10, 2025
Via
Benzinga
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?
↗
November 09, 2025
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.
Via
Benzinga
Why Teva Pharmaceutical Stock Rocked the Market Today
↗
November 05, 2025
The company delivered a convincing pair of beats in its third-quarter earnings report.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
November 05, 2025
Via
Benzinga
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
↗
November 05, 2025
Via
Benzinga
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
↗
November 05, 2025
Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.
Via
Benzinga
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
November 05, 2025
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...
Via
MarketMinute
Topics
Economy
Intellectual Property
Supply Chain
Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike
↗
November 05, 2025
Teva stock jumped Wednesday on better-than-expected quarterly metrics.
Via
Investor's Business Daily
Topics
Earnings
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock
↗
November 03, 2025
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock
Via
The Motley Fool
Topics
ETFs
Economy
Regulatory Compliance
Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally
↗
November 03, 2025
Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally
Via
The Motley Fool
Topics
Artificial Intelligence
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares
↗
October 29, 2025
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares
Via
The Motley Fool
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
↗
October 15, 2025
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
